MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy

Sponsor
Centre Hospitalier Universitaire de Besancon (Other)
Overall Status
Recruiting
CT.gov ID
NCT05333367
Collaborator
(none)
20
1
1
14.5
1.4

Study Details

Study Description

Brief Summary

The objective of this study is to describe the type of cell death induced by extracorporeal photochemotherapy, depending on the cell type, using a panel of complementary analysis techniques.

Condition or Disease Intervention/Treatment Phase
  • Other: Samples collection
N/A

Detailed Description

Extracorporeal photochemotherapy (ECP) is a cell therapy used for its immunomodulation and tolerance induction capabilities. Its main indications are the control of graft-versus-host (GVH) disease in hematopoietic cell allografts, treatment and control of rejection in solid organ transplantation and the treatment of cutaneous T-cell lymphoma. Data on the mechanisms of action of ECP remains very patchy. This lack of data limits the discussion on therapeutic regimens by disease.

ECP consists of repeated apheresis sessions to collect leukocytes from the patient. The cells are then photosensitized, irradiated with UVA and reinjected into the patient in a closed circuit. In the context of GVH, induced cell death would stimulate the expansion of regulatory cells (Treg), restore a Th1/Th2 balance and decrease Th17 polarization. The ECP also allows the expansion of Treg in solid organ transplantation. Conversely, ECP would restore or activate an antitumor immune response in cutaneous T lymphoma.

The type of cells collected and treated would play a major role in the effects obtained. However, these hypotheses must be consolidated, in particular by detailing the initial role of cell death. Several questions remain, on the chronology of cell death in the different treated subpopulations, on the uptake by phagocytes, but especially on the type of cell death induced according to the cell type (necroptosis, apoptosis, pyroptosis, autophagy). The data generated will allow for validation or detail of the mechanisms of resolution of the inflammation and/or the anti-tumour effect observed.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy
Actual Study Start Date :
Apr 15, 2022
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Other: Patients undergoing extracorporeal photochemotherapy

Other: Samples collection
Sampling of 2 samples on the extracorporeal photochemotherapy circuit, before and after sensitization with 8-MOP and UVA irradiation (without additional puncture)

Outcome Measures

Primary Outcome Measures

  1. Type of cell death induced by 8-MOP sensitization and UVA irradiation [24 hours]

    Caspase-3 activation in Western blot

  2. Type of cell death induced by 8-MOP sensitization and UVA irradiation [24 hours]

    Gasdermin D cleavage in Western blot

  3. Type of cell death induced by 8-MOP sensitization and UVA irradiation [24 hours]

    MLKL (mixed lineage kinase domain-like pseudokinase) phosphorylation in Western blot

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult patients

  • Treated with ECP for at least 1 month, for control of GVHD in hematopoietic cell allograft (acute or chronic GVHD), treatment and control of cellular or humoral rejection in solid organ transplantation (heart, lung, kidney) or in the treatment of cutaneous T-cell lymphoma

Exclusion Criteria:
  • Subjects with limited legal capacity.

  • Subjects judged by the investigator to be unlikely to comply with study procedures

  • Subjects with no social security coverage.

  • Pregnant women.

  • Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier Universitaire de Besançon Besançon France 25000

Sponsors and Collaborators

  • Centre Hospitalier Universitaire de Besancon

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Universitaire de Besancon
ClinicalTrials.gov Identifier:
NCT05333367
Other Study ID Numbers:
  • 2022/679
First Posted:
Apr 19, 2022
Last Update Posted:
Jun 1, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Universitaire de Besancon
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 1, 2022